首页 | 本学科首页   官方微博 | 高级检索  
     

纳米药物联合多肽介导肿瘤靶向研究进展
引用本文:赵鹏飞,甘丹,陈小飞,赵红天,戎欣玉.纳米药物联合多肽介导肿瘤靶向研究进展[J].中国医院药学杂志,2021,41(24):2602-2606.
作者姓名:赵鹏飞  甘丹  陈小飞  赵红天  戎欣玉
作者单位:1. 河北科技大学化学与制药工程学院, 河北 石家庄 050018;2. 河北省药物化工工程技术研究中心药剂实验室, 河北 石家庄 050018
摘    要:癌症发病率逐年提高,已超越心血管疾病成为许多国家人口死亡的首要原因。目前上市的许多治疗药物最大弊端之一是缺乏肿瘤靶向性,药物不良反应大。纳米药物联合多肽介导肿瘤靶向能有效地克服药物被机体吞噬清除,能定向地将药物运送到靶部位,有效提高到达癌症部位和肿瘤细胞的药物量,实现药物的主动靶向,增加药物抗肿瘤效果,实现精准治疗,是较新的研究方向。本文根据纳米药物中多肽在肿瘤部位的靶向机制和作用特点,介绍几种靶向性多肽及其应用和前景,包括细胞靶向肽、细胞穿膜肽和靶向穿膜双功能肽。

关 键 词:纳米药物  多肽  主动靶向  抗肿瘤  
收稿时间:2021-07-08

Research progress of nanoparticle drug combined with polypeptide mediated tumor targeting
ZHAO Peng-fei,GAN Dan,CHEN Xiao-fei,ZHAO Hong-tian,RONG Xin-yu.Research progress of nanoparticle drug combined with polypeptide mediated tumor targeting[J].Chinese Journal of Hospital Pharmacy,2021,41(24):2602-2606.
Authors:ZHAO Peng-fei  GAN Dan  CHEN Xiao-fei  ZHAO Hong-tian  RONG Xin-yu
Affiliation:1. School of Chemical & Pharmaceutical Engineering,Hebei University of Science & Technology,Hebei Shijiazhuang 050018,China;2. Laboratory of Pharmaceutical Formulations,Hebei Research Center of Pharmaceutical & Chemical Engineering,Hebei Shijiazhuang 050018,China
Abstract:With an annually rising incidence,cancer has overtaken cardiovascular disease as a leading cause of mortality in many countries.One of the biggest drawbacks of many therapeutic drugs currently on the market are a lack of tumor targeting and side effects of drugs.Nanodrugs with peptide-mediated tumor targeting can effectively overcome body clearing,home in to target sites,effectively expose a large amount of drug to cancer cells,realize active drug targeting,boost the anti-tumor effect of drugs and achieve accurate treatment.Based upon targeting mechanism and action characteristics of peptides in nanomedicines at tumor sites,several targeting peptides and their applications and prospects were introduced,including cell-targeting peptides,cell-penetrating peptides and targeting bifunctional peptides.
Keywords:nanodrug  polypeptide  active targeting  antitumor  
点击此处可从《中国医院药学杂志》浏览原始摘要信息
点击此处可从《中国医院药学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号